Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | PDE7A | Q13946 | 4/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24111018 | 0.80 | MAPT (0.41) | USP2MAPTALOX12RAB9ANPC1 | |
| SCHEMBL24110995 | 0.77 | ALOX12 (0.57) | USP2MAPTALOX12RAB9APDE7A | |
| SCHEMBL24111016 | 0.76 | IDO1 (0.46) | USP2MAPTALOX12RAB9ANPC1 | |
| SCHEMBL24090010 | 0.75 | USP2 (0.52) | USP2MAPTRAB9ANPC1KDM4E | |
| SCHEMBL24089986 | 0.73 | ALOX12 (0.55) | USP2MAPTALOX12RAB9ANPC1 | |
| SCHEMBL24090012 | 0.72 | TOP2A (0.60) | USP2MAPTRAB9ANPC1ALDH1A1 | |
| SCHEMBL24111024 | 0.72 | USP2 (0.43) | USP2MAPTRAB9ANPC1KDM4E | |
| SCHEMBL24090135 | 0.71 | USP2 (0.48) | USP2MAPTRAB9ANPC1KDM4E | |
| SCHEMBL30103292 | 0.71 | TGFBR1 (0.51) | USP2MAPTRAB9AKDM4EALDH1A1 | |
| SCHEMBL23958173 | 0.71 | ALDH1A1 (0.48) | USP2MAPTRAB9ANPC1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210387967-A1 | 2-HETEROARYL AMINOQUINAZOLINONE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2021-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210387967-A1 | 2-HETEROARYL AMINOQUINAZOLINONE DERIVATIVE | CRKL, CLIC4, CLIC1 | USP2 3746/4885MAPT 4749/4885ALOX12 3240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.